Expression of Matrix-Degrading Cysteine Proteinase Cathepsin K in Cholesteatoma Torsten Hansen, M.D., Ronald E

Total Page:16

File Type:pdf, Size:1020Kb

Expression of Matrix-Degrading Cysteine Proteinase Cathepsin K in Cholesteatoma Torsten Hansen, M.D., Ronald E Expression of Matrix-Degrading Cysteine Proteinase Cathepsin K in Cholesteatoma Torsten Hansen, M.D., Ronald E. Unger, Ph.D., Andreas Gaumann, M.D., Inga Hundorf, M.D., Jan Maurer, M.D., C. James Kirkpatrick, M.D., Ph.D., D.Sc., Jörg Kriegsmann, M.D., Ph.D. Institute of Pathology (TH, REU, AG, IH, CJK, JK) and Department of Oto-Rhino-Laryngology (JM), Johannes Gutenberg-University, Mainz, Germany Cholesteatoma is a nonneoplastic but potentially Cholesteatoma is a nonneoplastic lesion of the mid- aggressive lesion characterized by the presence of dle ear space or mastoid that is histologically char- keratin-producing squamous epithelium in the acterized by a progressive bone erosion of the os- middle ear space or mastoid. Cholesteatoma may sicles and surrounding bone. Several matrix- be congenital or acquired. Congenital cholesteato- degrading enzymes have been implicated as mas have been attributed to the proliferation of mediators of this bone erosion. Because the novel aberrant epithelial remnants. They are commonly cysteine proteinase cathepsin K has been shown to found in children with no history of ear disease. play a central role in bone resorption, we examined They are localized behind an intact tympanic mem- the expression of this enzyme in tissue specimens of brane. In contrast, most acquired cholesteatomas cholesteatoma. Tissue specimens of 9 patients with are associated with a perforated eardrum and a cholesteatoma were obtained during middle-ear history of chronic otitis media, trauma, or surgical surgery. Expression of cathepsin K mRNA was de- manipulation (1). Regardless of its origin, cho- termined by RT-PCR using specific primers. Immu- lesteatoma is histologically composed of keratina- nohistochemical analysis of cathepsin K protein ex- ceous debris in a concentric fashion surrounded by pression in tissue sections was performed by using keratinizing squamous epithelium that is also the streptavidin–alkaline phosphatase technique. called matrix (1, 2). The underlining subepithelial Expression of both cathepsin K mRNA and protein inflammatory tissue (i.e., perimatrix) consists of was detected in areas affected by cholesteatoma, mononuclear and multinucleated macrophages, whereas specimens of nonaffected ear cartilage and lymphocytes, neutrophils, fibroblasts, and endo- surrounding tissue were not positive. In addition, thelial cells (2, 3). cathepsin K was detected in numerous multinucle- Progressive bone erosion of the ossicles and sur- ated giant cells, particularly osteoclasts at the site of rounding bone is one of the hallmarks of cholestea- bone degradation. In contrast, keratinized squa- tomas. Originally, it was believed that this bone mous epithelium was negative for cathepsin K. erosion was due to the pressure from within the These data demonstrate that the matrix-degrading tumor mass (1, 2). However, numerous studies have cysteine proteinase cathepsin K may be involved in shown that collagenolytic enzymes are involved in bone erosion in cholesteatoma. Strong expression the destruction of the bone matrix as well. A variety of this collagenolytic enzyme in osteoclasts suggests of matrix-degrading proteinases have been found, that these cells are mainly involved in cathepsin such as several types of matrix metalloproteinases K–mediated bone destruction. (MMP), acid phosphatase, calpain Types I and II, and the cysteine proteinase cathepsin B (3–8). The KEY WORDS: Bone degradation, Cathepsin K, Cho- recently discovered cysteine proteinase cathepsin K lesteatoma, Osteoclasts. may play a crucial role in bone resorption because Mod Pathol 2001;14(12):1226–1231 it degrades large amounts of the major bone colla- gen Type I as well as the bone matrix protein os- teonectin (9, 10). Furthermore, it has been shown to be unique among mammalian proteinases because Copyright © 2001 by The United States and Canadian Academy of it is able to cleave the collagen molecule both inside Pathology, Inc. VOL. 14, NO. 12, P. 1226, 2001 Printed in the U.S.A. and outside of the collagen helix (10). Deficiency of Date of acceptance: August 8, 2001. cathepsin K results in pyknodysostosis, an autoso- Address reprint requests to: Torsten Hansen, M.D., Institute of Pathology, University of Mainz, Langenbeckstrasse 1, D-55101 Mainz, Germany; mal recessive osteochondrodysplasia (11). Expres- e-mail: [email protected]; fax: 49-6131-176604. sion of cathepsin K has been demonstrated in sev- 1226 eral chronic inflammatory lesions associated with cga tgg ag 3'. Cathepsin K (13): forward, 5' ggc caa bone destruction such as osteomyelitis (12), rheu- ctc aag aag aaa ac 3'; reverse, 5' gtg ctt gtt tcc ctt ctg matoid arthritis (13), osteoarthritis (14), nodular te- g 3'. cDNA was amplified by PCR under standard nosynovitis (15), and aseptic hip prosthesis loosen- conditions using Taq DNA-polymerase (Qiagen) ing (16). In addition, specific exogenous inhibitors and 5 pmol of both ␤-actin primers or 1 pm of both of cathepsin K have been shown to decrease the cathepsin K primers. In the case of PCR for ␤-actin, destruction of bone significantly (17). To provide a 3-step protocol was performed with 35 cycles and new insights in the pathogenesis of bone destruc- an annealing temperature of 65° C, denaturation at tion by cholesteatoma, we investigated the expres- 94° C for 2 minutes, extension at 72° C for 30 sec- sion of cathepsin K mRNA and protein in tissue onds, and a final extension at 72° C for 10 minutes specimens of patients with cholesteatoma. (Gene Amplification System 2400; PE Applied Bio- systems, Weiterstadt, Germany). Water was used instead of the cDNA as a negative control. MATERIALS AND METHODS In the case of PCR for cathepsin K, a 3-step pro- tocol was applied with 40 cycles and an annealing Patient Selection and Tissue Preparation temperature of 60° C, denaturation at 94° C for 2 Tissue samples of nine patients (all male; age minutes, extension at 72° C for 30 seconds, and final range: 9–71 years) with an acquired cholesteatoma extension at 72° C for 10 minutes. As a positive were obtained during middle-ear surgery. Examina- control for cathepsin K, we used cDNA of cathepsin tion of cathepsin K mRNA expression by RT-PCR K (13) that were cloned in an LXSN vector. Water was performed on six cholesteatoma specimens was applied instead of the cDNA for negative and on 2 specimens of ear cartilage and surround- control. ing external ear canal skin that were macroscopi- Reaction products were analyzed by running PCR cally not affected by cholesteatoma. These samples samples on a 0.8% agarose gel (Life Technologies, were rapidly frozen in liquid nitrogen without prior Paisley, UK) and staining with ethidium bromide. Ϫ fixation and were stored at 80° C. For immuno- The size of the amplification products was con- histochemical analysis of cathepsin K protein ex- firmed by a commercial molecular weight marker ϭ pression, cholesteatoma specimens (n 9) and (100-bp DNA ladder; New England BioLab, Beverly, ϭ nonaffected tissue probes (n 2) were fixed in 4% MA). PBS-buffered formaldehyde and embedded in par- affin according to standard protocols. Immunohistochemistry RNA Isolation Four-micrometer paraffin sections were mounted Frozen tissue specimens were disrupted using a on silane-coated slides, dewaxed, and rehydrated Polytron homogenizer (Kinematica, Littau, Switzer- through alcohol gradients. Staining with monoclonal land). Total RNA was then isolated from homoge- antibodies against human cathepsin K (clone 182– nized specimens using the RNeasy Mini Kit (Qiagen, 12G5; Chemicon, Temecula, CA) was performed us- Hilden, Germany) with the additional incubation ing the streptavidine-alkaline phosphatase technique. step, using RNase-free DNase (Qiagen) for 15 minutes As control, mouse immunoglobulins (Cymbus Bio- at room temperature, according to the manufactur- technology, Chandlers Ford, UK) were used to replace er’s instructions. RNA samples were stored at Ϫ80° C the primary antibodies. All steps were performed at until used. room temperature. Slides were treated with an avi- din–biotin blocking kit (Vector, Burlingame, CA), after which nonspecific binding of immunoglobulins was cDNA Synthesis (Reverse Transcription) blocked by incubation with 4% nonfat dried bovine The RNA templates were incubated with a master milk (Sigma, St. Louis, MO) and 2% normal horse mix (Qiagen) including RNase-free water, 1ϫ reac- serum (Vector) in Tris buffer (pH 7.6). Primary anti- tion buffer, 0.5 mM dNTP Mix, 1.0 ␮M oligo-dT bodies diluted 1:2000 and negative control (diluted primer, RNase inhibitor (30 units/␮L), and 4 U per 1:200) in Tris buffer (pH 7.6) were then incubated for reaction of Omniscript reverse transcriptase in a 1:2 1 hour, followed by a 30-minute incubation with bi- dilution for 60 minutes at 37° C. After reverse tran- otinylated horse anti-mouse IgG (Vector). Slides were scription samples were stored at Ϫ20° C. then covered with streptavidine-conjugated alkaline phosphatase (1:50 dilution; DAKO, Glostrup, Den- mark) for 30 minutes. The color reaction was per- Polymerase Chain Reaction formed using the new fuchsin method. Endogenous The following specific primer pairs were applied alkaline phosphatase was blocked by adding levami- for the subsequent PCR. ␤-actin: forward, 5' gac ctg sole (Sigma) to the substrate solution. Color develop- act gac tac ctc atg a 3'; reverse, 5' agc att tgc cgt gga ment was stopped by immersing the slides in Tris Matrix-Degrading Cysteine Proteinase Cathepsin K (T. Hansen et al.) 1227 buffer (pH 7.6). Finally, slides were counterstained squamous epithelium of the matrix (Fig. 2). This with Mayer’s hematoxylin (Merck, Darmstadt, Ger- proteinase was abundantly expressed in numerous many) and mounted in Kaiser’s glycerol gelatin osteoclasts at sites of bone destruction (Fig. 3). (Merck). Nonaffected ear cartilage and surrounding external Slides were examined and photographed with a ear skin did not reveal cathepsin K expression (Fig. Leica Microscope DMRX (Leitz, Wetzlar, Germany). 4). Negative controls did not exhibit staining. Microscopic evaluation of the slides was performed according to previously described methods (15).
Recommended publications
  • Solutions to Detect Apoptosis and Pyroptosis
    Powerful Tools for In vitro Fluorescent Imaging in Cancer Research Jackie Carville May 11, 2016 About Us Products and Services • Custom Assay Services – Immunoassay design and development – Antibody purification/conjugation • Consumable Reagents – ELISA Solutions – Cell-permeant Fluorescent Probes for detection of cell death • Products for research use only. Not for use in diagnostic procedures. ELISA Solutions • ELISA Wash Buffer • PBS • Substrates • Stop Solutions • Plates • Coating Buffers • Blocking Buffers • Conjugate Stabilizers • Assay Diluents • Sample Diluents Custom Services • Antibody Conjugation • Immunoassay Design • Immunoassay Development • Lyophilization • Plate Coating Overview of ICT’s Fluorescent Probes FOR DETECTION OF: • Active caspases • Caspases/Cathepsins in real time • Mitochondrial Health • Cytotoxicity • Serine Proteases Today’s Agenda • FLICA • FLISP • Magic Red • Cell Viability • Mito PT • Oxidative Stress • Cytotoxicity FLICA • FLICA – Fluorescent Labeled Inhibitor of Caspases • In vitro, whole cell detection of caspase activity in apoptotic or caspase-positive cells • Available in green, red, and far red assays FLICA Cancer Research Applications • FLICA is the most accurate and sensitive method of apoptosis detection • Can identify four stages of cell death in one sample • Detect poly caspase activity or individual caspase enzymes How FLICA A. INACTIVE CASPASE (ZYMOGEN) works… prodomain B. CASPASE PROCESSING FMK Fluorescent Reporter YVAD tag C. ACTIVATED CASPASE (HETERO-TETRAMER) D. BINDING OF FLICA Sample
    [Show full text]
  • The Osteoclast-Associated Protease Cathepsin K Is Expressed in Human Breast Carcinoma1
    CANCER RESEARCH57. 5386-5390. December I, 19971 The Osteoclast-associated Protease Cathepsin K Is Expressed in Human Breast Carcinoma1 Amanda J. Littlewood-Evans,' Graeme Bilbe, Wayne B. Bowler, David Farley, Brenda Wlodarski, Toshio Kokubo, Tetsuya Inaoka, John Sloane, Dean B. Evans, and James A. Gallagher Novartis Pharina AG, CH-4002 Base!. Switzerland (A. I. L-E., G. B., D. F., D. B. El; Human Bone Cell Research Group, Department of Human Anatomy and Cell Biology 1W. B. B., B. W., J. A. G.J, and Department of Pathology If. S.), University of Liverpool, Liverpool 5.69 3BX, United Kingdom [W. B. B., B. W., J. S., J. A. G.]; and Takarazuka Research Institute, Novartis Pharma lid., Takarazuka 665, Japan IT. K., T. LI ABSTRACT (ZR75—l,Hs578Tduct, BT474, ZR75—30,BT549, and T-47D), adenocarci noma (MDA-MB-231, SK-BR3, MDA-MB-468, and BT2O), and breast car Human cathepsin K is a novel cysteine protease previously reported cinoma[MVLNandMTLN,transfectedMCF-7-derivedclonesobtainedfrom to be restricted in its expression to osteoclasts. Immunolocalization of Dr. J. C. Nicolas (Unit de Recherches sur Ia Biochemie des Steroides Insern cathepsin K in breast tumor bone metastases revealed that the invading U58, Montpelier, France), and MCF-7]. The MCF-7 cells were obtained from breast cancer cells expressed this protease, albeit at a lower intensity two different sources, ATCC and Dr. Roland Schuele (Tumor Klinik, Freiburg, than in osteoclasts. In situ hybridization and immunolocalization stud Germany). These are indicated in the figure legend as clone 1 (ATCC) and ies were subsequently conducted to demonstrate cathepsin K mRNA clone 2 (Dr.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • A Cysteine Protease Inhibitor Blocks SARS-Cov-2 Infection of Human and Monkey Cells
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.23.347534; this version posted October 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells Drake M. Mellott,1 Chien-Te Tseng,3 Aleksandra Drelich,3 Pavla Fajtová,4,5 Bala C. Chenna,1 Demetrios H. Kostomiris1, Jason Hsu,3 Jiyun Zhu,1 Zane W. Taylor,2,9 Vivian Tat,3 Ardala Katzfuss,1 Linfeng Li,1 Miriam A. Giardini,4 Danielle Skinner,4 Ken Hirata,4 Sungjun Beck4, Aaron F. Carlin,8 Alex E. Clark4, Laura Beretta4, Daniel Maneval6, Felix Frueh,6 Brett L. Hurst,7 Hong Wang,7 Klaudia I. Kocurek,2 Frank M. Raushel,2 Anthony J. O’Donoghue,4 Jair Lage de Siqueira-Neto,4 Thomas D. Meek1.*, and James H. McKerrow#4,* Departments of Biochemistry and Biophysics1 and Chemistry,2 Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, 3Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas, 77755-1001, 4Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 5Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610 Prague, Czech Republic, 6Selva Therapeutics, and 7Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, 5600 Old Main Hill, Utah State University, Logan, Utah, 84322, 8Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.9Current address: Biological Sciences Division, Pacific Northwest National Laboratory, 902 Battelle Blvd, Richland, WA 99353.
    [Show full text]
  • Cysteine Cathepsin Proteases: Regulators of Cancer Progression and Therapeutic Response
    REVIEWS Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response Oakley C. Olson1,2 and Johanna A. Joyce1,3,4 Abstract | Cysteine cathepsin protease activity is frequently dysregulated in the context of neoplastic transformation. Increased activity and aberrant localization of proteases within the tumour microenvironment have a potent role in driving cancer progression, proliferation, invasion and metastasis. Recent studies have also uncovered functions for cathepsins in the suppression of the response to therapeutic intervention in various malignancies. However, cathepsins can be either tumour promoting or tumour suppressive depending on the context, which emphasizes the importance of rigorous in vivo analyses to ascertain function. Here, we review the basic research and clinical findings that underlie the roles of cathepsins in cancer, and provide a roadmap for the rational integration of cathepsin-targeting agents into clinical treatment. Extracellular matrix Our contemporary understanding of cysteine cathepsin tissue homeostasis. In fact, aberrant cathepsin activity (ECM). The ECM represents the proteases originates with their canonical role as degrada- is not unique to cancer and contributes to many disease multitude of proteins and tive enzymes of the lysosome. This view has expanded states — for example, osteoporosis and arthritis4, neuro­ macromolecules secreted by considerably over decades of research, both through an degenerative diseases5, cardiovascular disease6, obe- cells into the extracellular
    [Show full text]
  • The P53-Cathepsin Axis Cooperates with ROS to Activate Programmed Necrotic Death Upon DNA Damage
    The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage Ho-Chou Tua,1, Decheng Rena,1, Gary X. Wanga, David Y. Chena, Todd D. Westergarda, Hyungjin Kima, Satoru Sasagawaa, James J.-D. Hsieha,b, and Emily H.-Y. Chenga,b,c,2 aDepartment of Medicine, Molecular Oncology, bSiteman Cancer Center, and cDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved November 25, 2008 (received for review August 19, 2008) Three forms of cell death have been described: apoptosis, autophagic cells that are deprived of the apoptotic gateway to mediate cyto- cell death, and necrosis. Although genetic and biochemical studies chrome c release for caspase activation (Fig. S1) (9–11, 19, 20). have formulated a detailed blueprint concerning the apoptotic net- Despite the lack of caspase activation (20), DKO cells eventually work, necrosis is generally perceived as a passive cellular demise succumb to various death signals manifesting a much slower death resulted from unmanageable physical damages. Here, we conclude an kinetics compared with wild-type cells (Fig. 1A, Fig. S2, and data active de novo genetic program underlying DNA damage-induced not shown). To investigate the mechanism(s) underlying BAX/ necrosis, thus assigning necrotic cell death as a form of ‘‘programmed BAK-independent cell death, we first examined the morphological cell death.’’ Cells deficient of the essential mitochondrial apoptotic features of the dying DKO cells. Electron microscopy uncovered effectors, BAX and BAK, ultimately succumbed to DNA damage, signature characteristics of necrosis in DKO cells after DNA exhibiting signature necrotic characteristics.
    [Show full text]
  • A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens Th
    Molecular Pharmacology Fast Forward. Published on July 5, 2018 as DOI: 10.1124/mol.118.112730 This article has not been copyedited and formatted. The final version may differ from this version. MOL #112730 1 Title Page MiniReview for Molecular Pharmacology Allergen Delivery Inhibitors: A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens Through Structure-Based Protease Inhibitor Design Downloaded from molpharm.aspetjournals.org Jihui Zhang, Jie Chen, Gary K Newton, Trevor R Perrior, Clive Robinson at ASPET Journals on September 26, 2021 Institute for Infection and Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom (JZ, JC, CR) State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P.R. China (JZ) Domainex Ltd, Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL, United Kingdom (GKN, TRP) Molecular Pharmacology Fast Forward. Published on July 5, 2018 as DOI: 10.1124/mol.118.112730 This article has not been copyedited and formatted. The final version may differ from this version. MOL #112730 2 Running Title Page Running Title: Allergen Delivery Inhibitors Correspondence: Professor Clive Robinson, Institute for Infection and Immunity, St George’s, University of London, SW17 0RE, UK [email protected] Downloaded from Number of pages: 68 (including references, tables and figures)(word count = 19,752) 26 (main text)(word count = 10,945) Number of Tables: 3 molpharm.aspetjournals.org
    [Show full text]
  • Targeting Cathepsin K for the Treatment of Osteoporosis – Focus
    Drugs or :he Future 2010, 35(8): 643-,;49 THOMSON Rf.CJTfRS \' (opvtlght ~ lOIO Prous Sd1.?no:•, SA U. <11 it~ lir.f:>nsor!=. At~ right~ r~~Q1~d CCC: 0.377-Lll82/W10 001: 10 1353/~of.2010 35 8 .152~'l'.2 F{E\/!EW J\f<TICLE TARGETING CATHEPSIN K FOR THE TREATMENT OF OSTEOPOROSIS: FOCUS ON ODANACATIB E.M. Lewiecki New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA CONTENTS density (BMD) and bone strength are stable. II bone resorption SummJry .......... ....... .. , . .... ..... • ...... ... .643 exceeds bone formation, as occurs in postmenopausat estrogen· deficient women, there is a net loss of bone over time that may ulti· Introduction ........ ........ • .. .... .. • ..... ..... .. .643 mately result in osteoporosis and increased risk of fractures (1) . Cathepsin K inhibitors .......... .. ...... .. .... ... .... .645 Osteoporosis is a common disease associated with increased Conclusions ....... ....... .. .. .. ...... ....... .648 morbidity, increased mortality and high henlthcare costs due to frac­ Referencr.s .......... ..•. .. .... ... • . ... • .. .. , .. .648 tures (2). Bone resorption requires the attachment of an osteoclast to the bone surface by means of a "sealing zone" in order to create a self· SUMMARY contained compartment between the bone surface and the adjacent Cathepsin K is a lysosomal cysteine protease expressed by osteoclasts ruffled border of the osteoclast (3). The acidic microenvironment that degrades type I collagen during the process of bone remodeling. beneath the osteoclast demineralizes the bone and exposes the Postmenopovsal osteoporosis (PMO) is a disease of excessive bone underlylng matrix, which is then degraded through the action of cys­ tvrnover, wit/1 an imbalance between bone resorption and bone formo - teine proteases (4). Since cathepsin K is the most abundant cysteine tion that covses loss of bone strength and increased risk of fractures.
    [Show full text]
  • Chapter 11 Cysteine Proteases
    CHAPTER 11 CYSTEINE PROTEASES ZBIGNIEW GRZONKA, FRANCISZEK KASPRZYKOWSKI AND WIESŁAW WICZK∗ Faculty of Chemistry, University of Gdansk,´ Poland ∗[email protected] 1. INTRODUCTION Cysteine proteases (CPs) are present in all living organisms. More than twenty families of cysteine proteases have been described (Barrett, 1994) many of which (e.g. papain, bromelain, ficain , animal cathepsins) are of industrial impor- tance. Recently, cysteine proteases, in particular lysosomal cathepsins, have attracted the interest of the pharmaceutical industry (Leung-Toung et al., 2002). Cathepsins are promising drug targets for many diseases such as osteoporosis, rheumatoid arthritis, arteriosclerosis, cancer, and inflammatory and autoimmune diseases. Caspases, another group of CPs, are important elements of the apoptotic machinery that regulates programmed cell death (Denault and Salvesen, 2002). Comprehensive information on CPs can be found in many excellent books and reviews (Barrett et al., 1998; Bordusa, 2002; Drauz and Waldmann, 2002; Lecaille et al., 2002; McGrath, 1999; Otto and Schirmeister, 1997). 2. STRUCTURE AND FUNCTION 2.1. Classification and Evolution Cysteine proteases (EC.3.4.22) are proteins of molecular mass about 21-30 kDa. They catalyse the hydrolysis of peptide, amide, ester, thiol ester and thiono ester bonds. The CP family can be subdivided into exopeptidases (e.g. cathepsin X, carboxypeptidase B) and endopeptidases (papain, bromelain, ficain, cathepsins). Exopeptidases cleave the peptide bond proximal to the amino or carboxy termini of the substrate, whereas endopeptidases cleave peptide bonds distant from the N- or C-termini. Cysteine proteases are divided into five clans: CA (papain-like enzymes), 181 J. Polaina and A.P. MacCabe (eds.), Industrial Enzymes, 181–195.
    [Show full text]
  • Odanacatib, a Cathepsin K Inhibitor for the Treatment of Osteoporosis and Other Skeletal Disorders Associated with Excessive Bone Remodeling E Michael Lewiecki
    !Drugs 200912(12):7~()-809 (~ Tliornso11 Reuters (Scientific) ltd ISSN 2040· 3410 DRUC PROFILE Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling E Michael Lewiecki Address New Mexico Clinic.ii Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA !:mail: lewiecki@aolcorn Odanacatib (MK·0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under license from Ce/era Croup, for the treatment of osteoporosis and bone metastases. Cathepsin K, a lysosomol cysteine protease that is expressed by osteoclasts during the process of bone resorption, acts as the major col/agenase responsible for the degradation of the organic bone matrix during the bone remodeling process. Because excessive bone remodeling is a key element in the pathogenesis of postmenopousal osteoporosis and other skeletal disorders, cathepsin K is a potential target for therapeutic intervention. In a phase II clinical trial, weekly doses of odanacatib increased bone mineral density (BMD) and reduced bone turnover markers in postmenopausol women with low BMD. No tolerability concerns or evidence of skeletol toxicity were reported. Phase Ill trials, including a trial to evaluate the effects of odanocatib on froctt1re risk in up to 20,000 women with postmenopausol osteoporosis, were ongoing or recruiting participants at the time of publication. Odanacatib is a promising agent for the management of postmenopausal osteoporosis and other skeletal disorders associated with excessive bone remade/Ing. Introduction Therapeutic Odanacatib Osteoporosis is a common skeletal disease characterized by low bone mineral density (BMD) and poor bone quality Originator Celera Group that reduces bone strength and increases the risk of fractures [506066].
    [Show full text]
  • Cathepsin K-Mediated Notch1 Activation Contributes to Neovascularization in Response to Hypoxia
    ARTICLE Received 10 Jan 2014 | Accepted 9 Apr 2014 | Published 4 Jun 2014 DOI: 10.1038/ncomms4838 Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia Haiying Jiang1,2,3,*, Xian Wu Cheng1,4,5,6,*, Guo-Ping Shi7, Lina Hu1, Aiko Inoue1, Yumiko Yamamura4, Hongxian Wu4, Kyosuke Takeshita4, Xiang Li1,5, Zhe Huang1, Haizhen Song1,8, Masashi Asai9, Chang-Ning Hao4, Kazumasa Unno4, Teruhiro Koike2, Yoshiharu Oshida2, Kenji Okumura4, Toyoaki Murohara4 & Masafumi Kuzuya1 Cysteine proteases play important roles in pathobiology. Here we reveal that cathepsin K (CatK) has a role in ischaemia-induced neovascularization. Femoral artery ligation-induced ischaemia in mice increases CatK expression and activity, and CatK-deficient mice show impaired functional recovery following hindlimb ischaemia. CatK deficiency reduces the levels of cleaved Notch1 (c-Notch1), Hes1 Hey1, Hey2, vascular endothelial growth factor, Flt-1 and phospho-Akt proteins of the ischaemic muscles. In endothelial cells, silencing of CatK mimicked, whereas CatK overexpression enhanced, the levels of c-Notch1 and the expression of Notch downstream signalling molecules, suggesting CatK contributes to Notch1 processing and activates downstream signalling. Moreover, CatK knockdown leads to defective endothelial cell invasion, proliferation and tube formation, and CatK deficiency is associated with decreased circulating endothelial progenitor cells-like CD31 þ /c-Kit þ cells in mice following hindlimb ischaemia. Transplantation of bone marrow-derived mononuclear cells from CatK þ / þ mice restores the impairment of neovascularization in CatK À / À mice. We conclude that CatK may be a potential therapeutic target for ischaemic disease. 1 Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Aichiken, Japan.
    [Show full text]
  • Allergen Delivery Inhibitors: Characterisation of Potent and Selective Inhibitors of Der P 1 and Their Attenuation of Airway Responses to House Dust Mite Allergens
    International Journal of Molecular Sciences Article Allergen Delivery Inhibitors: Characterisation of Potent and Selective Inhibitors of Der p 1 and Their Attenuation of Airway Responses to House Dust Mite Allergens Jihui Zhang 1,2, Jie Chen 1, Jie Zuo 1,3, Gary K. Newton 4, Mark R. Stewart 4, Trevor R. Perrior 4, David R. Garrod 5 and Clive Robinson 1,* 1 Institute for Infection & Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK; [email protected] (J.Z.); [email protected] (J.C.); [email protected] (J.Z.) 2 State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 3 BOE Technology Center, BOE Technology Group Co., Ltd., Beijing 100176, China 4 Domainex Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, UK; [email protected] (G.K.N.); [email protected] (M.R.S.); [email protected] (T.R.P.) 5 Faculty of Biology Medicine and Health, University of Manchester, Manchester M13 9PL, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)20-8725-5620 Received: 31 August 2018; Accepted: 5 October 2018; Published: 15 October 2018 Abstract: Group 1 allergens of house dust mites (HDM) are globally significant triggers of allergic disease. They are considered as initiator allergens because their protease activity enables the development of allergy to a spectrum of unrelated allergens from various sources. This initiator-perpetuator function identifies Group 1 HDM allergens as attractive drug design targets for the first small-molecule approach directed towards a non-human, root cause trigger of allergic disease.
    [Show full text]